# Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

> **NCT07105124** · PHASE1 · COMPLETED · sponsor: **Otsuka Beijing Research Institute** · enrollment: 24 (actual)

## Conditions studied

- Healthy Subjects (HS)

## Interventions

- **DRUG:** Sibeprenlimab

## Key facts

- **NCT ID:** NCT07105124
- **Lead sponsor:** Otsuka Beijing Research Institute
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07105124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07105124, "Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07105124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*